Skip header and navigation

2 records – page 1 of 1.

The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.

https://arctichealth.org/en/permalink/ahliterature97848
Source
Clin Cancer Res. 2010 Mar 15;16(6):1845-55
Publication Type
Article
Date
Mar-15-2010
Author
Anna M Dahlin
Richard Palmqvist
Maria L Henriksson
Maria Jacobsson
Vincy Eklöf
Jörgen Rutegård
Ake Oberg
Bethany R Van Guelpen
Author Affiliation
Department of Medical Biosciences, Pathology, and Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden. anna.dahlin@medbio.umu.se
Source
Clin Cancer Res. 2010 Mar 15;16(6):1845-55
Date
Mar-15-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Colorectal Neoplasms - genetics
CpG Islands - genetics
DNA Methylation
Female
Gene Expression Regulation, Neoplastic
Humans
Immunoenzyme Techniques
Male
Microsatellite Instability
Middle Aged
Mutation - genetics
Phenotype
Prognosis
Promoter Regions, Genetic
Proto-Oncogene Proteins B-raf - genetics
Survival Rate
Abstract
PURPOSE: The aim of this study was to relate the CpG island methylator phenotype (CIMP; characterized by extensive promoter hypermethylation) to cancer-specific survival in colorectal cancer, taking into consideration relevant clinicopathologic factors, such as microsatellite instability (MSI) screening status and the BRAF V600E mutation. EXPERIMENTAL DESIGN: Archival tumor samples from 190 patients from the Northern Sweden Health and Disease Study (NSHDS) and 414 patients from the Colorectal Cancer in Umeå Study (CRUMS), including 574 with cancer-specific survival data, were analyzed for an eight-gene CIMP panel using quantitative real-time PCR (MethyLight). MSI screening status was assessed by immunohistochemistry. RESULTS: CIMP-low patients had a shorter cancer-specific survival compared with CIMP-negative patients (multivariate hazard ratio in NSHDS, 2.01; 95% confidence interval, 1.20-3.37; multivariate hazard ratio in CRUMS, 1.48; 95% confidence interval, 1.00-2.22). This result was similar in subgroups based on MSI screening status and was statistically significant in microsatellite stable (MSS) tumors in NSHDS. For CIMP-high patients, a shorter cancer-specific survival compared with CIMP-negative patients was observed in the MSS subgroup. Statistical significance was lost after adjusting for the BRAF mutation, but the main findings were generally unaffected. CONCLUSIONS: In this study, we found a poor prognosis in CIMP-low patients regardless of MSI screening status, and in CIMP-high patients with MSS. Although not consistently statistically significant, these results were consistent in two separate patient groups and emphasize the potential importance of CIMP and MSI status in colorectal cancer research.
PubMed ID
20197478 View in PubMed
Less detail

[The law does not prevent health care professionals from reading patient data].

https://arctichealth.org/en/permalink/ahliterature105084
Source
Lakartidningen. 2013 Dec 4-17;110(49-50):2216-7
Publication Type
Article